The procedure of blood testing for detecting and testing mood disorders have become a strong ray of hope for the medical community facilitating the process of coming up with better treatments for the mood disorder conditions.

At present, no blood tests have been devised for diagnosing and treating mood disorders. This medical procedure must be wistfully developed as relying on patients to rate the severity of their symptoms and on the cliniciansâ impression may endure a limited effect on the chances of accurate treatment and the development of new drug.

The distinguished team of researchers from Indiana University School of Medicine have proposed a new way instead in order to identify blood biomarkers, which in turn would lead them them to  determine mood state.

The research results that are on the top of the list of candidate blood biomarker genes, essentially comprise five genes that play a part in myelination and six other genes responsible for growth factor signaling. All of these genes have resulted in having a distinctively differential expression on the brains of patients suffering from mood disorders. An average score rested upon an experimental panel of ten top candidate biomarkers who were put under observation — five undergoing the high mood test, five undergoing the low mood test — reflects a particular amount of sensitivity and specificity for the states of both high mood and low mood, when put under two separate studies.

The research provides very strong and positive ground for the fact that blood biomarkers may offer a hugely informative purview of brain functioning and state of disease. The research results also reflect a fascinating overlap between genes responsible for cancer biology and those that trigger mood regulation.